In the latest version of the Human Cells Atlas, 2,000 researchers in 83 countries have defined, one by one, some 60 million cells.
Our mission is to create a map of all human cells, says Israeli biologist Aviv Regev, who began the project in 2016 and leads the international consortium together with the German biologist Sarah Teichmann, from the Wellcome Sanger Institute in Cambridge (UK).
Regev, who is on leave from the Massachusetts Institute of Technology (MIT) and has a management position at US biotech company Genentech, says she believes the cross-continental team is halfway to its goal.
While children study some examples of cells at school such as neurons, red blood cells, white blood cells, and platelets, nobody knows how many types there really are, explains the scientist.
We didnt know how many genes we had until the Human Genome Project. This is a similar case, she says.
The Human Cells Atlas aims to catalog all cell types and their multiple subtypes, but also to locate them precisely in the human body and have a picture of the exact composition of each organ: what we are made of and why diseases arise.
Spanish immunologist Cecilia Domnguez Conde is among the main authors of the latest version, which was reported last week in the journal Science. The researchers describe the detailed profile of more than a million cells; presenting cross-referenced data from 33 organs of the human body, such as the heart, skin and lungs.
Domnguez Condes team is based at the Wellcome Sanger Institute, and has focused on the cells of the immune system.
We have discovered how cells adapt to different environments, says the immunologist, who will begin leading her own laboratory at the Human Technopole, a new research center in Milan (Italy), in June.
The diversity of cell types within the immune system is absolutely incredible, says Domnguez Conde, adding that the work had previously focused on the blood circulating in the body, while now, we study the cells in different tissues and we see new mechanisms.
The immunologist notes that there is a new generation of cancer treatments, the so-called CAR-T, in which white T lymphocyte blood cells are extracted from the patient. Then, using genetic engineering, they are redesigned in the laboratory to increase their ability to destroy cancer cells.
Biology textbooks have traditionally spoken of about 300 cell types in the human body, but the authors of the atlas have found 500 types in the last million cells analyzed. Understanding this astonishing diversity will make it possible to improve vaccines, increase the efficacy of antitumor therapies, facilitate regenerative medicine and develop new treatments for rare and common diseases, according to Regev, who now has a management position at the US biotech company Genentech.
While biology textbooks usually teach that there are about 300 cell types in the human body, the authors of the Human Cell Atlas have now found some 500 types. This new understanding, says Aviv Regev, will contribute to improving vaccines and antitumor therapies as well as regenerative medicine and new treatments for both rare and common diseases.
A mutation in a gene can cause a disease, but although all cells share the same DNA, the problem will only appear in cells that have that particular gene activated.
We have found many unexpected cells that have active disease-associated genes, says Regev.
For example, we have observed non-muscle cells in muscle tissue expressing genes that cause rare muscle diseases.
This is important, because if we want to develop treatments we need to know the cells in order to target them, explains the biologist.
Regev also highlights possible applications of these findings to regenerative medicine, a specialization that tries to rebuild damaged organs using new cells.
To get it right, we need to generate cells with the right properties. The atlas is a reference to ensure that the cells generated in the laboratory have the desired characteristics, he says.
Neuroscientist Rafael Yuste, a professor at Columbia University in New York, applauds the latest version of the atlas.
This batch of results is historic. It is one of the first salvos of what will be a torrent of studies in the next decade that will classify all cell types in the body, says Yuste, who has not participated in the investigation. The Spanish neuroscientist was the founder of BRAIN, a billion-dollar project sponsored in 2013 by then-US president, Barack Obama, to obtain a map of the human brain.
Yuste is optimistic. The new technologies, called transcriptomics, allow cells to be placed in narrow channels and trapped one by one in oily droplets, analyzing their active genes in a manner that is fast, automated and cheap.
The first steps of this strategy have been spectacular. For example, in the United States, the Allen Institute of Brain Sciences has classified all the cells in a part of the cerebral cortex of the mouse, generating for the first time a list of all the types of neurons in an area of the brain, says Yuste, who has collaborated on that project.
Yuste recalls how the father of neuroscience, Santiago Ramn y Cajal, discovered in 1888, using a rudimentary microscope, that neurons were individual cells. Now, says Yuste, it is giant consortia like his BRAIN initiative and the Human Cell Atlas doing this work.
It is a huge effort, says the professor. It will have a fundamental impact on science and medicine, since, in the end, everything that the brain, or the body, does, is cooked up between cell types.
Originally posted here:
Latest Human Cells Atlas reveals more of the unknown world inside our bodies - EL PAS in English
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022
- Study refutes long-held belief that the Corin gene causes hypertension in African Americans - University of Alabama at Birmingham - September 14th, 2022
- Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss - Yahoo... - September 14th, 2022
- Solving medical mysteries with genetics: The Penn Neurogenetics Therapy Center | Penn Today - Penn Today - September 14th, 2022
- Pharmacogenetics Testing in Psychiatry/Depression Market Will Rise at a CAGR 9.5% by 2029 and is segmented by Test Type, Gene Type, Patient Type,... - September 14th, 2022
- Scientists have created a mathematical model for the dynamics of nanoparticles and viruses in cells - EurekAlert - September 14th, 2022
- Fierce Biotech Names ReCode Therapeutics as One of its Fierce 15 Biotech Companies of 2022 - Business Wire - September 14th, 2022
- Foundation Medicine, Relay Therapeutics to Develop FoundationOne CDx for FGFR2 Inhibitor - GenomeWeb - September 14th, 2022
- Downstream Processing in the Age of Precision Medicine: Trends and Challenges - Technology Networks - September 14th, 2022
- BU receives NIH award to increase diversity of STEM and biomedical science workforce - EurekAlert - September 14th, 2022
- Leveraging Best-of-Breed Algorithms for Accuracy in Precision Medicine - BioSpace - September 14th, 2022
- Pitt researchers are leading the way toward a Google Maps of cells - University of Pittsburgh - September 14th, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 14th, 2022
- Smart Immune Bolsters Management Team with Medical and Technical Appointments - GlobeNewswire - September 14th, 2022
- A blood-based miRNA signature for early non-invasive diagnosis of preeclampsia - BMC Medicine - BMC Medicine - September 14th, 2022
- dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes - August 15th, 2022
- Cellular & Gene Therapy Guidances | FDA - August 15th, 2022
- The Silver Lining Of Innovation in Genetic Medicine - Pharmaceutical Executive - August 15th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 15th, 2022
- Canadian family raised $3.5M to develop individualized gene therapy for son's rare condition - National Post - August 15th, 2022
- Auburn University researchers first to map blue catfish genome - Office of Communications and Marketing - August 15th, 2022
- Las Vegas baby diagnosed with rare genetic mutation - KVOA Tucson News - August 15th, 2022
- Personalised medicine made in hospitals can revolutionise the way diseases are treated the challenge now will be implementing it - The Conversation... - August 15th, 2022
- 'Guardian of the Genome' and the 'WASp' team up to repair DNA damage - Penn State Health News - August 15th, 2022
- Novartis bid to repurpose rare disease drug for cancer falls short in third trial - BioPharma Dive - August 15th, 2022
- Abnormal protein could be a common link between all forms of motor neurone disease - University of Sydney - August 15th, 2022
- Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy - PR Newswire - August 6th, 2022
- FDA halts testing of Beam's base editing cancer therapy - BioPharma Dive - August 6th, 2022
- OHSU advancing first-of-its-kind strategy to overcome infertility - OHSU News - August 6th, 2022
- Viral Vectors Manufacturing Market: Increase in the Number of Gene Therapy Candidates due to Rapid Development of Diseases to Drive the Market -... - August 6th, 2022
- The association of APOE genotype with COVID-19 disease severity | Scientific Reports - Nature.com - August 6th, 2022
- Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform that Enables Precision Medicine at Scale - Business Wire - August 6th, 2022
- Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - PR Newswire - August 6th, 2022
- Reshaping how doctors and researchers share phenotypic information: first GA4GH standard published by ISO - EurekAlert - August 6th, 2022
- Research Spots Gene That Raises Alzheimer's Risk for Women - HealthDay News - July 4th, 2022
- If You Have This Blood Type, Be Worried About Your Health Eat This Not That - Eat This, Not That - July 4th, 2022
- The NRC HL Holmes Award supports the development of technology to target and treat basal-like breast cancer - National Research Council Canada -... - July 4th, 2022
- UT Health San Antonio on global team discovering Alzheimers clues - San Antonio Report - July 4th, 2022
- Identities in harmony | Penn Today - Penn Today - July 4th, 2022
- The Global Genotyping Market size is expected to reach $30.9 billion by 2028, rising at a market growth of 14.7% CAGR during the forecast period -... - July 4th, 2022
- VA research will bring precision medicine to mental health - VAntage Point - VAntage Point Blog - June 11th, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UC develops new lung cancer treatment | University Of Cincinnati - University of Cincinnati - June 11th, 2022
- CTGT transactions: Beware of ripples in the safe harbor - JD Supra - June 11th, 2022
- Startup offers genetic testing that promises to predict healthiest embryo - WHYY - June 11th, 2022
- WHRY Funds Studies on Sex Differences in Treating Gastrointestinal Cancers, Bone Health in Transgender Youth, and the Greater Risk for Alzheimer's... - June 11th, 2022
- NIH awards USC more than $16 million for research on vascular dysfunction and Alzheimer's disease | Keck School of Medicine of USC - University of... - June 11th, 2022
- Effect of Metformin on Glycemic Control | DMSO - Dove Medical Press - June 11th, 2022
- Overcoming the Challenges of Cell and Gene Therapy Facilities - Genetic Engineering & Biotechnology News - June 3rd, 2022
- Organoids test gene therapies for Pitt-Hopkins syndrome - Spectrum - June 3rd, 2022
- Gene Therapy Successfully Treats Spinal Cord Injuries Without Side Effects - SciTechDaily - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - EurekAlert - June 3rd, 2022
- Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program - Business Wire - June 3rd, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 3rd, 2022
- Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision... - June 3rd, 2022
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA)... - June 3rd, 2022
- Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer - DocWire News - June 3rd, 2022
- Winship receives $11 million grant from the National Cancer Institute to improve immunotherapy for lung cancer - EurekAlert - June 3rd, 2022
- Gene Editing Service Market Report 2022-2028 | Keyplayers- Caribou Biosciences, CRISPR Therapeutics, Merck KGa, Editas Medicine The Greater... - June 3rd, 2022
- Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO -... - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - University of Rochester - May 28th, 2022
- Welsh wins 2022 Shaw Prize in Life Sciences and Medicine | Carver College of Medicine - The University of Iowa - May 28th, 2022